| ASSET | QUARTER | % RETURN |
|---|---|---|
Ainos (AIMD) | Q3 2015 | 3,802.44% |
GreenPro Capital (GRNQ) | Q3 2015 | 614.29% |
Akari Therapeutics (AKTX) | Q3 2015 | 300.05% |
Anavex Life Sciences (AVXL) | Q3 2015 | 208.2% |
Ambow Education (AMBO) | Q3 2015 | 170% |
authID (AUID) | Q3 2015 | 150% |
Workhorse (WKHS) | Q3 2015 | 139.95% |
ProMIS Neurosciences (PMN) | Q3 2015 | 133.33% |
CEA Industries (CEAD) | Q3 2015 | 121.82% |
Nixxy (NIXX) | Q3 2015 | 110% |
Neurogene (NGNE) | Q3 2015 | 99.57% |
Forward Industries (FORD) | Q3 2015 | 99.26% |
Rocket Pharmaceuticals (RCKT) | Q3 2015 | 88.76% |
Can Fite Biopharma Ltd ADR (CANF) | Q3 2015 | 86.32% |
Zynex (ZYXI) | Q3 2015 | 80.14% |
JX Luxventure (JXJT) | Q3 2015 | 78.04% |
CleanSpark (CLSK) | Q3 2015 | 76% |
EDAP TMS (EDAP) | Q3 2015 | 71.47% |
Enveric Biosciences (ENVB) | Q3 2015 | 64.55% |
Educational Development (EDUC) | Q3 2015 | 63.87% |
Lifevantage (LFVN) | Q3 2015 | 62% |
Xenetic Biosciences (XBIO) | Q3 2015 | 61.36% |
Applied DNA Sciences (APDN) | Q3 2015 | 60.5% |
Exelixis (EXEL) | Q3 2015 | 55.83% |
Eterna Therapeutics (ERNA) | Q3 2015 | 54.55% |
